{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:32:25Z","timestamp":1770067945719,"version":"3.49.0"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,6]],"date-time":"2006-01-06T00:00:00Z","timestamp":1136505600000},"content-version":"vor","delay-in-days":66,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> Therapy with either deferiprone (DFP) or deferoxamine (DFO) is inadequate in achieving negative iron balance in many patients with thalassemia. There are mounting theoretical, experimental, and clinical evidences of increased efficacy when therapy includes both chelating agents. DFP and DFO chelate excess iron in different ways without affecting each other's metabolism. When both chelators are administered simultaneously, they interact either in an additive or synergistic manner, probably through \u201cshuttling\u201d iron from DFP to DFO. Iron\u2010balance studies have shown that the use of both agents on the same day can induce negative iron balance in all patients. Long\u2010term combined therapy with DFO with DFP results in considerable reduction of both ferritin levels and liver iron concentration as well as significant improvement in cardiac siderosis and function. This therapeutic regimen is well tolerated and safe, even though it may be related to a small increase in the incidence of agranulocytosis compared with DFP monotherapy. Apart from using both agents simultaneously, sequential administration of DFP and DFO has also shown promising results. Combining the available iron chelators offers many therapeutic options that can be tailored to each patient individually. It is an exciting advance in treating hemosiderosis in thalassemic patients.<\/jats:p>","DOI":"10.1196\/annals.1345.020","type":"journal-article","created":{"date-parts":[[2005,12,8]],"date-time":"2005-12-08T23:18:51Z","timestamp":1134083931000},"page":"175-182","source":"Crossref","is-referenced-by-count":26,"title":["Combined Therapy with Deferoxamine and Deferiprone"],"prefix":"10.1111","volume":"1054","author":[{"given":"ANTONIS","family":"KATTAMIS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,7,8]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1182\/blood.V86.5.2008.bloodjournal8652008","article-title":"Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo","volume":"86","author":"Shalev O.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01447.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90030-7"},{"key":"e_1_2_7_5_2","first-page":"604a","article-title":"Optimizing chelation therapy: combining deferiprone and desferrioxamine","volume":"96","author":"Grady R.W.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_7_6_2","first-page":"1423","article-title":"Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion","volume":"88","author":"Kattamis A.","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1067\/mlc.2001.116487"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.3.792"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200550"},{"key":"e_1_2_7_10_2","first-page":"ELT07","article-title":"Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta\u2010thalassemia patients","volume":"89","author":"Athanassiou\u2010Metaxa M.","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_7_11_2","first-page":"493","article-title":"Combined oral and parenteral iron chelation in beta thalassaemia major","volume":"55","author":"Balveer K.","year":"2000","journal-title":"Med. J. Malaysia"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200407000-00011"},{"key":"e_1_2_7_13_2","unstructured":"Farmaki K.et al.2004. Combined chelation therapy in thalassemia major; how long it takes to reduce body iron overload at safety margins [Abstr.]. Hematol. J.5(Suppl 2): 194."},{"key":"e_1_2_7_14_2","first-page":"517a","article-title":"Efficacy of combined chelation therapy with subcutaneous desferrioxamine and oral deferiprone in patients with thalassemia major [Abstr.]","volume":"102","author":"Francis S.","year":"2003","journal-title":"Blood"},{"key":"e_1_2_7_15_2","unstructured":"Hadjigraviel M.et al.2003. Improvements in cardiac function using combination chelation therapy [Abstr.].InProceedings of the 9th International Conference on Thalassemia and Hemoglobinopathies. O79. TIF Palermo Italy."},{"key":"e_1_2_7_16_2","first-page":"505a","article-title":"A 12\u2010months' trial of a combined regimen of deferiprone and deferoxamine in patients with thalassemia major","volume":"102","author":"Kattamis A.","year":"2003","journal-title":"Blood"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04240.x"},{"key":"e_1_2_7_18_2","unstructured":"Origa R.et al.2003. Combination therapy with desferrioxamine and deferiprone in thalassemia major [Abstr.].InProceedings of the 9th International Conference on Thalassemia and Hemoglobinopathies. O48. TIF Palermo Italy."},{"key":"e_1_2_7_19_2","doi-asserted-by":"crossref","first-page":"28b","DOI":"10.1182\/blood.V104.11.3766.3766","article-title":"Efficient iron chelation resulting in improved myocardial performance with combined desferrioxamine and deferiprone in beta thalassemia major patients [Abstr.]","volume":"104","author":"Pathare A.V.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.01002.x"},{"key":"e_1_2_7_21_2","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"Borgna\u2010Pignatti C.","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-3886(00)00100-4"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05202.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.4.1229.004k32_1229_1236"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00075.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00335.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0820-0"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/10715769900300491"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0807"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2004.10.003"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.2.705.bloodjournal882705"},{"key":"e_1_2_7_32_2","unstructured":"Meo A.et al.2004. NTBI values in thalassemia patients on combined chelation (DFO+L1) treatment or on monotherapy (DFO or L1). Hematol. J.5(Suppl. 2): S84."},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03554.x"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01866.x"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01560.x"},{"key":"e_1_2_7_36_2","doi-asserted-by":"crossref","first-page":"982a","DOI":"10.1182\/blood.V104.11.3611.3611","article-title":"Safety and efficacy of alternate desferrioxamine and deferiprone compared to desferrioxamine alone in the treatment of iron overload in transfusion\u2010dependent thalassemia patients [Abstr.]","volume":"104","author":"Galanello R.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1867"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1345.020","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1345.020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T20:52:21Z","timestamp":1695675141000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1345.020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1196\/annals.1345.020"],"URL":"https:\/\/doi.org\/10.1196\/annals.1345.020","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}